title: Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection.
abstract: BACKGROUND
  Identifying persons with latent tuberculosis infection (LTBI) is crucial to the goal of TB elimination. A whole-blood interferon gamma (IFN-gamma) assay, the QuantiFERON-TB test, is a promising in vitro diagnostic test for LTBI that has potential advantages over the tuberculin skin test (TST).
  
  
  OBJECTIVE
  To compare the IFN-gamma assay with the TST and to identify factors associated with discordance between the tests.
  
  
  METHODS
  Prospective comparison study conducted at 5 university-affiliated sites in the United States between March 1, 1998 and June 30, 1999.
  
  
  METHODS
  A total of 1226 adults (mean age, 39 years) with varying risks of Mycobacterium tuberculosis infection or documented or suspected active TB, all of whom underwent both the IFN-gamma assay and the TST.
  
  
  METHODS
  Level of agreement between the IFN-gamma assay and the TST.
  
  
  RESULTS
  Three hundred ninety participants (31.8%) had a positive TST result and 349 (28.5%) had a positive IFN-gamma assay result. Overall agreement between the IFN-gamma assay and the TST was 83.1% (kappa = 0.60). Multivariate analysis revealed that the odds of having a positive TST result but negative IFN-gamma assay result were 7 times higher for BCG-vaccinated persons compared with unvaccinated persons. The IFN-gamma assay provided evidence that among unvaccinated persons with a positive TST result but negative IFN-gamma assay result, 21.2% were responding to mycobacteria other than M tuberculosis.
  
  
  CONCLUSIONS
  For all study participants, as well as for those being screened for LTBI, the IFN-gamma assay was comparable with the TST in its ability to detect LTBI, was less affected by BCG vaccination, discriminated responses due to nontuberculous mycobacteria, and avoided variability and subjectivity associated with placing and reading the TST.
authors.affiliation: Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, 1600 Clifton Rd, Mailstop E10, Atlanta, GA 30333, USA. gym6@cdc.gov
authors.forename: G H
authors.initials: GH
authors.lastname: Mazurek
authors.forename: P A
authors.initials: PA
authors.lastname: LoBue
authors.forename: C L
authors.initials: CL
authors.lastname: Daley
authors.forename: J
authors.initials: J
authors.lastname: Bernardo
authors.forename: A A
authors.initials: AA
authors.lastname: Lardizabal
authors.forename: W R
authors.initials: WR
authors.lastname: Bishai
authors.forename: M F
authors.initials: MF
authors.lastname: Iademarco
authors.forename: J S
authors.initials: JS
authors.lastname: Rothel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001500:BCG Vaccine; D005260:Female; D006801:Humans; D007159:Immunologic Tests; D007371:Interferon-gamma / Q000097:blood*; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification*; D011446:Prospective Studies; D014373:Tuberculin; D014374:Tuberculin Test; D014376:Tuberculosis / Q000175:diagnosis*
chemical_list: D001500:BCG Vaccine; D014373:Tuberculin; D007371:Interferon-gamma